Calcium

Body Calcium Distribution and Daily Balance

• Abundance and Compartmentalization:

  • Calcium is the most abundant mineral and a primary intracellular/extracellular messenger in the human body.

  • Bone Matrix: Contains approximately $99\%$ of total body calcium, serving as the structural reservoir.

  • Intracellular and Extracellular Fluid (ECF): Contains approximately $1\%$ of total body calcium, which executes all rapid signaling, cell excitation, and metabolic functions.

• Daily Calcium Homeostasis (based on a $\sim 1000\,\text{mg/day}$ diet):

  • Dietary Intake: $\sim 1000\,\text{mg/day}$.

  • Intestinal Absorption and Secretion:

  • Intestinal mucosa secretes $\sim 200\,\text{mg/day}$ into the gut lumen.

  • Gross intestinal absorption is $ rối 400-500\,\text{mg/day}$, yielding a **net intestinal absorption** of$\sim 200-300\,\text{mg/day}.\n * Unabsorbed calcium excreted in feces accounts for \sim 800\,\text{mg/day}.\n * **Renal Handling**:\n * Glomerular filtration filters \sim 10{,}000\,\text{mg/day}$($\sim 10\,\text{g/day}) of calcium into the tubule lumen.\n * Renal tubular system reabsorbs 98-99\% of filtered calcium.\n * Urinary excretion removes \sim 200-300\,\text{mg/day}$(approximately$2\% of filtered load).\n * **Bone Remodeling Exchange**:\n * Accretion (osteoblastic rebuilding) and resorption (osteoclastic breakdown) continuously exchange \sim 500\,\text{mg/day} between bone matrix and ECF.\n * In healthy adults, net skeletal exchange is zero (absorption equals excretion). A chronic negative balance forces skeletal resorption to defend serum concentrations at the expense of structural bone strength.\n\n\n\n# Blood Calcium Fractions and Acid-Base Physiology\n\n* **Serum Total Calcium Reference Range**: Normal total calcium ranges between 2.1-2.6\,\text{mmol/L}$($8.5-10.5\,\text{mg/dL}).\n\n* **Three Plasma Fractions**:\n 1. **Free Ionized Calcium (\text{Ca}^{2+})**:\n * Accounts for 50\%$of total serum calcium ($1.1-1.3\,\text{mmol/L}).\n * It is ultrafilterable through membranes.\n * Constitutes the sole **physiologically active fraction** that regulates cellular functions and drives endocrine feedback loops via parathyroid hormone (PTH), calcitriol, and calcitonin.\n 2. **Protein-Bound Calcium**:\n * Accounts for 40\% of total serum calcium.\n * Non-ultrafilterable fraction.\n * Primarily bound to plasma **albumin** (and to a lesser degree, globulins). This bound fraction is physiologically inactive and serves as a circulating storage reservoir.\n 3. **Complexed Calcium**:\n * Accounts for 10\% of total serum calcium.\n * It is ultrafilterable through membranes.\n * Complexed with small inorganic plasma anions, including phosphate, citrate, and bicarbonate.\n * **Ultrafilterable Calcium Pool**: The combination of free ionized (50\%$) and complexed ($10\%$) fractions forms the ultrafilterable pool ($60\% of total calcium) available for renal glomerular filtration.\n\n\n\n\n\n* **Acid-Base Dynamics and Ionized Calcium Equilibrium**:\n * Hydrogen ions (\text{H}^+$) and calcium ions ($\text{Ca}^{2+}) compete directly for negative binding sites on serum protein (albumin) carboxyl groups.\n * **Acidemia (Acidosis / Low pH)**:\n * An increased concentration of free plasma \text{H}^+ leads to increased binding of protons to albumin.\n * \text{H}^+$displaces$\text{Ca}^{2+}$from albumin binding sites, driving a transient **increase in free ionized$\text{Ca}^{2+} concentration** without altering total serum calcium.\n * **Alkalemia (Alkalosis / High pH)**:\n * A decreased concentration of free plasma \text{H}^+ causes protons to dissociate from albumin.\n * Unbound negative sites on albumin readily bind free \text{Ca}^{2+}$, causing a transient **decrease in free ionized$\text{Ca}^{2+} concentration**.\n * Acute hyperventilation-induced respiratory alkalosis can trigger symptomatic acute hypocalcemic tetany despite a normal total calcium level.\n * **Anion/Ligand Binding Shifts**: Free ionized \text{Ca}^{2+} concentrations can also decrease transiently through binding or complexation with elevated levels of free fatty acids (FFA), citrate (e.g., rapid blood transfusions), EDTA, muscle proteins, or inorganic phosphate.\n\n\n\n# Albumin-Corrected Calcium Formulas and Diagnostic Testing\n\n* **Diagnostic Modalities**:\n * **Total Calcium Measurement**: Included in standard routine biochemical panels. Inexpensive and widely available, but dependent on serum albumin concentrations.\n * **Ionized Calcium Measurement**: The clinical gold standard for assessing physiological calcium status. Requires collection using heparinized blood gas syringes handled strictly under anaerobic conditions. Essential in critical care settings, massive transfusions, and chronic kidney disease (CKD).\n\n* **Albumin-Correction Adjustment Formulas**:\n * When serum albumin deviates from normal (40\,\text{g/L}$or$4.0\,\text{g/dL}), total serum calcium must be corrected to prevent pseudohypocalcemia or pseudohypercalcemia.\n * **SI Units** (Calcium in \text{mmol/L}$, Albumin in$\text{g/L}):\n    \text{Albumin-Corrected Total Ca}^{2+}\,(\text{mmol/L}) = \text{Measured Total Ca}^{2+}\,(\text{mmol/L}) + [40 - \text{Serum Albumin}\,(\text{g/L})] \times 0.02\n * **Non-SI Units** (Calcium in \text{mg/dL}$, Albumin in$\text{g/dL}):\n    \text{Albumin-Corrected Total Ca}^{2+}\,(\text{mg/dL}) = \text{Measured Total Ca}^{2+}\,(\text{mg/dL}) + [4.0 - \text{Serum Albumin}\,(\text{g/dL})] \times 0.8\n\n* **Clinical Application**:\n * In **hypoalbuminemia** (e.g., nephrotic syndrome, cirrhosis, malnutrition), reduced albumin levels lead to a low total serum calcium value, while the biologically active ionized \text{Ca}^{2+} remains normal. Calculating the corrected total calcium prevents inappropriate treatment for hypocalcemia.\n\n\n\n# Bone Physiology, Cells, and Mineralization\n\n* **Skeletal Mineral Matrix**:\n * The skeleton houses 99\%$of total body calcium and$\sim 85\%$of total body phosphate, stored primarily as hydroxyapatite crystals [$\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2].\n * **Rapid Exchange Pool**: Amorphous surface crystals on bone structural units rapidly equilibrate with the ECF over minutes to hours without cellular remodeling.\n * **Mineralization Dynamics**: Bone matrix deposition requires an adequate extracellular solubility product of \text{Ca} \times \text{Phosphate} and sufficient active calcitriol.\n\n* **Tri-Cellular Bone Remodeling Unit**:\n 1. **Osteoblasts**:\n * Bone-forming cells derived from mesenchymal stem cells.\n * Synthesize and deposit organic bone matrix (osteoid) composed of Type I collagen and ground substance.\n * Express **surface PTH receptors**.\n * Secrete **Alkaline Phosphatase (ALP)**, a key biomarker of osteoblastic synthetic activity and bone turnover.\n 2. **Osteoclasts**:\n * Large, multinucleated bone-destroying cells derived from monocyte/macrophage lineage.\n * Resorb mineralized bone and matrix, releasing \text{Ca}^{2+}$and$\text{PO}_4^{3-} into the circulation.\n * **Do not express PTH receptors**; their activity is controlled indirectly via signaling from osteoblasts.\n * Degrade Type I collagen matrix, releasing **hydroxyproline** into the urine as a biomarker of bone resorption.\n 3. **Osteocytes**:\n * Terminally differentiated osteoblasts entrapped within calcified lacunae.\n * Interconnected via extensive canalicular networks to sense mechanical strain, matrix compression, tension, and fluid flow.\n * **Osteocytic Osteolysis**: Osteocytes rapidly resorb surrounding perilacunar bone matrix, pumping \text{Ca}^{2+}$and$\text{PO}_4^{3-} directly into the ECF fluid system during acute physiological demands.\n\n\n\n# Intestinal Calcium Transport Mechanisms\n\n* **Intestinal Absorption Overview**:\n * The gastrointestinal tract is the sole external entry route for systemic calcium.\n * Absorption occurs via two pathways across the enterocyte epithelium:\n\n1. **Transcellular Pathway (Active Absorption)**:\n * An active, energy-dependent pathway driven by active Vitamin D (**calcitriol**).\n * **Apical Entry**: \text{Ca}^{2+} enters the enterocyte down an electrochemical gradient via epithelial calcium channels, primarily **TRPV6** (Transient Receptor Potential Vanilloid member 6).\n * **Cytosolic Chaperoning**: Intracellular \text{Ca}^{2+} is bound to **calbindin** proteins, which buffer cytosolic free calcium and transport it across the cytoplasm to the basolateral membrane.\n * **Basolateral Extrusion**: Active transport into peritubular capillary blood is executed by plasma membrane \text{Ca}^{2+}\text{-ATPase}$(**PMCA**) pumps and$\text{Na}^+/\text{Ca}^{2+} exchangers (**NCX**).\n * **Regulated Demand**: Calcitriol upregulates TRPV6 and calbindin expression over hours to days. This active route **dominates during low dietary calcium intake** to maximize intestinal calcium extraction.\n\n2. **Paracellular Pathway (Passive Absorption)**:\n * A passive, non-saturable transport route between enterocytes via tight junctions driven by luminal-to-serosal concentration gradients.\n * **Dominates during high dietary calcium intake**, where large luminal calcium concentrations drive passive transepithelial flux.\n\n\n\n# Segmental Renal Calcium and Phosphate Handling\n\n* **Renal Clearance Overview**:\n * Approximately \sim 10\,\text{g/day}$($10{,}000\,\text{mg/day}$) of calcium is filtered through the glomeruli. The nephron reabsorbs$98-99\%$of this filtered load, leaving$\sim 2\%$($\sim 200-300\,\text{mg/day}) to be excreted in urine.\n\n* **Segmental Nephron Breakdown**:\n 1. **Proximal Convoluted Tubule (PCT)**:\n * **Reabsorbs \sim 65\%** of filtered calcium.\n * **Mechanism**: Passive, **paracellular route** solvent-drag transport coupled to bulk sodium and water reabsorption.\n * **Regulation**: Passive coupling means PCT calcium reabsorption increases with ECF volume contraction (increased proximal sodium reabsorption) and decreases with ECF volume expansion.\n * **Phosphate Handling**: PCT is the main site of renal phosphate reabsorption (\sim 80\% filtered load) via sodium-phosphate cotransporters. **PTH directly inhibits** proximal phosphate reabsorption, causing marked phosphaturia.\n 2. **Thick Ascending Limb (TAL) of Henle's Loop**:\n * **Reabsorbs \sim 25-30\%** of filtered calcium.\n * **Mechanism**: Passive **paracellular route** driven by a **lumen-positive transepithelial potential** (\mathbf{+} lumen relative to interstitium).\n * **Ionic Circuit**: Sodium-potassium-2-chloride cotransporters (**NKCC2**) reabsorb ions, while apical Renal Outer Medullary Potassium channels (**ROMK**) recycle \text{K}^+$back into the lumen, generating the positive luminal voltage. Tight junction permeability is mediated by **Claudin-16** ($\text{CLDN16}$) and **Claudin-19** ($\text{CLDN19}).\n * **Pharmacological Action**: **Loop diuretics** (e.g., Furosemide) block NKCC2, abolishing the lumen-positive potential and paracellular calcium reabsorption, resulting in net calciuresis.\n 3. **Distal Convoluted Tubule (DCT)**:\n * **Reabsorbs \sim 10\%** of filtered calcium.\n * **Mechanism**: Active, regulated **transcellular route**.\n * **Transporters**: \text{Ca}^{2+} enters through apical **TRPV5** channels, binds intracellular **calbindin-D28k**, and is extruded across the basolateral membrane.\n * **Hormonal Fine-Tuning**: **PTH directly stimulates** DCT transcellular calcium reabsorption. **Thiazide diuretics** act in the DCT to enhance net calcium reabsorption.\n 4. **Collecting Duct**:\n * **Reabsorbs \sim 0.5\%**; regulated via ADH/AQP2 pathways.\n\n\n\n* **Renal Calcium-Sensing Receptor (CaSR) Control in the TAL**:\n * Epithelial cells in the TAL express basolateral **CaSR** facing peritubular capillary blood.\n * **High Plasma \text{Ca}^{2+} Effect**:\n 1. Activates basolateral CaSR, which sends inhibitory intracellular signals that directly **inhibit NKCC2 and ROMK**.\n 2. Inhibiting NKCC2/ROMK collapses the lumen-positive potential.\n 3. CaSR activation directly **reduces tight junction permeability** (Claudin-16/19 complex).\n 4. **Net Result**: Inhibits paracellular \text{Ca}^{2+} reabsorption, causing urinary excretion of excess calcium (calciuresis). Loop diuretics mimic this molecular inhibition.\n\n\n\n# Endocrine Control of Calcium and Phosphate Homeostasis\n\n* **Hormonal Axis Overview**:\n * Systemic calcium homeostasis is regulated by three main hormones operating across three target tissues (Bone, Kidney, Intestine):\n\n1. **Parathyroid Hormone (PTH)**:\n * **Synthesis & Structure**: An 84-amino-acid peptide hormone synthesized by **chief cells** of the four parathyroid glands located on the posterior aspect of the thyroid gland. Circulating half-life is \sim 4\,\text{minutes}.\n * **Primary Action**: Primary physiological regulator to **raise plasma [\text{Ca}^{2+}]$** and **lower plasma$[\text{PO}_4^{3-}]**.\n * **Secretion Regulation**:\n * **Stimulated by**: A drop in plasma free ionized [\text{Ca}^{2+}]$(hypocalcemia) or a rise in plasma$[\text{PO}_4^{3-}] (hyperphosphatemia).\n * **Inhibited by**: A rise in plasma free ionized [\text{Ca}^{2+}]$(hypercalcemia) or active calcitriol ($1,25-(\text{OH})_2\text{D}_3), which binds vitamin D receptors in chief cells to repress PTH gene transcription.\n * **Chief Cell Calcium-Sensing Receptor (CaSR)**:\n * Parathyroid chief cell membranes express surface CaSR coupled to \text{G}_q$and$\text{G}_i proteins.\n * Binding of high extracellular \text{Ca}^{2+} to CaSR triggers intracellular signaling that represses preproPTH expression, blocks proPTH processing, and prevents PTH vesicle exocytosis.\n * **Calcimimetics** (e.g., Cinacalcet): Allosteric modulators that activate CaSR, mimicking high \text{Ca}^{2+} to suppress PTH secretion.\n\n\n\n2. **Calcitriol (1,25\text{-dihydroxyvitamin D}_3)**:\n * **Multi-Organ Synthesis Pathway**:\n * **Skin**: 7-Dehydrocholesterol is converted to Cholecalciferol (Vitamin \text{D}_3$) via solar ultraviolet (UVB) radiation. Alternatively, Vitamin$\text{D}_3$or Ergocalciferol (Vitamin$\text{D}_2) are ingested from dietary sources.\n * **Liver**: Hepatic Vitamin D 25-hydroxylase converts Vitamin D into 25\text{-(OH) Vitamin D} (Calcidiol), the principal circulating storage form.\n * **Kidney**: Renal proximal tubular **1\alpha\text{-hydroxylase}$** converts calcidiol into active **$1,25\text{-(OH)}_2\text{ Vitamin D}_3 (Calcitriol)**.\n * **Regulation of 1\alpha\text{-hydroxylase}**:\n * **Stimulated by**: Elevated PTH, hypocalcemia, and low serum phosphate.\n * **Inhibited by**: Hyperphosphatemia, calcitriol (negative feedback), and Fibroblast Growth Factor 23 (FGF23).\n * **Primary Action**: Promotes bone mineralization by increasing systemic absorption of both calcium and phosphate.\n\n\n\n3. **Calcitonin ("The Physiological Brake")**:\n * **Synthesis**: Peptide hormone synthesized and secreted by **parafollicular cells (C-cells)** of the thyroid gland.\n * **Secretion Stimuli**: Secreted in response to elevated plasma free ionized [\text{Ca}^{2+}] (hypercalcemia); inhibited by hypocalcemia.\n * **Primary Function**: Lowers elevated plasma calcium and phosphate concentrations by directly binding and **inhibiting osteoclasts** (stopping osteoclastic bone resorption) and osteocytes (stopping osteocytic osteolysis).\n * **Renal Function**: Exerts a minor, transient inhibitory effect on renal tubular calcium and phosphate reabsorption.\n\n\n\n\n\n# Detailed Direct and Indirect Mechanisms of PTH Action\n\n* **Direct and Indirect Mechanisms by Organ Target**:\n\n 1. **Action on Bone**:\n * **Direct Action on Osteocytes**: Binds surface receptors to induce rapid osteocytic osteolysis, pumping \text{Ca}^{2+} into canalicular fluid and ECF within minutes.\n * **Direct Action on Osteoblasts**: Binds G-protein coupled receptors on osteoblasts, inducing structural remodeling and gene transcription.\n * **Indirect Activation of Osteoclasts**:\n * Osteoclasts lack functional PTH receptors.\n * PTH binding to osteoblasts stimulates expression of **Macrophage Colony-Stimulating Factor (M-CSF)** and **RANKL** (Receptor Activator of Nuclear Factor \kappa\text{B} Ligand).\n * RANKL binds RANK surface receptors on pre-osteoclasts, driving fusion, maturation, and activation into functional osteoclasts.\n * Osteoblasts also release **Osteoprotegerin (OPG)**, a soluble decoy receptor that binds RANKL and prevents RANK activation. PTH suppresses OPG expression, shifting the OPG/RANKL ratio toward osteoclastogenesis.\n * **Laboratory Biomarkers of Bone Remodeling**:\n * **Serum Alkaline Phosphatase (ALP)**: Released by active osteoblasts during bone formation/remodeling.\n * **Urinary Hydroxyproline**: Matrix breakdown product released during osteoclastic degradation of collagen matrix.\n\n 2. **Action on Kidney**:\n * Binds basolateral PTH-1 receptors in the **Distal Convoluted Tubule (DCT)**, directly upregulating transcellular \text{Ca}^{2+} reabsorption.\n * Binds receptors in the **Proximal Convoluted Tubule (PCT)**, inducing endocytosis and degradation of apical sodium-phosphate cotransporters, leading to **marked phosphaturia** (lowers plasma phosphate).\n * Directly stimulates PCT expression of **1\alpha\text{-hydroxylase}**, accelerating renal synthesis of active calcitriol.\n\n 3. **Action on Intestine**:\n * **Indirect Mechanism**: PTH has minimal direct actions on enterocytes. It acts indirectly by upregulating renal $1\alpha\text{-hydroxylase}, elevating circulating calcitriol levels. Calcitriol then drives transcellular intestinal absorption of dietary calcium and phosphate.

Physiological Roles of Calcium in Human Physiology

1. Neuromuscular Excitability: Modulates voltage-gated $\text{Na}^+$ channel opening thresholds via electrostatic membrane shielding.

2. Excitation-Contraction Coupling in Muscle: Binds Troponin C in skeletal/cardiac muscle and Calmodulin in smooth muscle to expose actin-myosin binding cross-bridges.

3. Excitation-Secretion Coupling: Influx through voltage-gated calcium channels triggers exocytosis of neurotransmitters at presynaptic terminals and hormones (e.g., insulin, PTH) from endocrine glands.

4. Blood Coagulation Cascade: Functions as essential enzymatic cofactor Factor IV in both intrinsic and extrinsic coagulation pathways.

5. Cell Adhesion and Structural Integrity: Maintains extracellular domain cadherin assembly for inter-cellular tight junctions and desmosomes.

6. Intracellular Second Messenger Signaling: Activates Protein Kinase C (PKC), Calmodulin-dependent protein kinases (CaMK), and regulates motility/enzymatic cascades.

7. Structural Mineral Matrix: Forms hydroxyapatite lattice providing compressive strength to skeleton and dentition.

8. Lactation: Serves as a primary constituent of breast milk, requiring maternal homeostatic adjustments during lactation.

Pathophysiology and Clinical Manifestations of Calcium Imbalances

• Electrophysiological Basis of Neuromuscular Excitability:

  • Potassium ($\text{K}^+$) concentration gradient determines the Resting Membrane Potential ($E_m$).

  • Extracellular Calcium ($\text{Ca}^{2+}$) concentration sets the Threshold Potential ($E_t$) required to open voltage-gated $\text{Na}^+$ channels.

  • Hypocalcemia Effect: Low extracellular $\text{Ca}^{2+}$ reduces electrostatic screening of negative membrane surface charges. This lowers the threshold potential ($E_t$) closer to the resting potential ($E_m$), making the membrane hyperexcitable (nerves fire with minimal stimulation).

  • Hypercalcemia Effect: High extracellular $\text{Ca}^{2+}$ increases charge screening, raising the threshold potential ($E_t$) further away from resting potential ($E_m$). This depresses membrane excitability (nerves become refractory to stimulation).

• Hypocalcemia:

  • Biochemical Definition: Free ionized $\text{Ca}^{2+} < 1.1\,\text{mmol/L}$ or corrected total calcium $< 2.1\,\text{mmol/L}$.

  • Clinical Signs and Symptoms:

  • Neuromuscular Hyperexcitability: Perioral tingling, acral paresthesias, muscle cramps, tetany (carpopedal spasms), laryngospasm, confusion, and generalized seizures.

  • Chvostek Sign: Tapping the facial nerve trunk anterior to the ear lobe over the parotid gland induces involuntary twitching of ipsilateral facial muscles.

  • Trousseau Sign: Inflating a blood pressure cuff on the upper arm above systolic pressure for 3 minutes induces ischemia-enhanced carpal spasm (flexion of wrist/MCP joints with extension of interphalangeal joints).

  • Cardiac Changes: Prolonged QT interval on ECG, risking ventricular arrhythmias.

  • Etiologies:

  • Low PTH (Hypoparathyroidism): Damage/removal of parathyroid glands during thyroidectomy, autoimmune destruction, or severe hypomagnesemia (magnesium deficiency impairs PTH release and causes end-organ resistance).

  • High/Normal PTH: Vitamin D deficiency (most common cause globally), Chronic Kidney Disease (loss of renal $1\alpha\text{-hydroxylase}$), malabsorption syndromes, pseudohypoparathyroidism (end-organ PTH resistance).

  • Other: Acute hyperventilation (respiratory alkalosis), acute pancreatitis (saponification of calcium in retroperitoneum), loop diuretics.

• Hypercalcemia:

  • Biochemical Definition: Corrected total calcium $> 2.6\,\text{mmol/L}$; clinical symptoms typically manifest at levels $> 3.0\,\text{mmol/L}$.

  • Clinical Signs and Symptoms ("Stones, Bones, Abdominal Groans, Psychic Moans"):

  • Stones: Nephrolithiasis (calcium oxalate/phosphate renal stones), polyuria, polydipsia, dehydration (hypercalcemia inhibits ADH action in collecting ducts, causing nephrogenic diabetes insipidus).

  • Bones: Bone aches, osteopenia, osteoporosis, pathologic fractures.

  • Abdominal Groans: Constipation, anorexia, nausea, vomiting, peptic ulcer disease (calcium stimulates gastrin secretion), acute pancreatitis.

  • Psychic Moans: Fatigue, muscle weakness, hyporeflexia, cognitive impairment, depression, confusion, stupor, coma.

  • Cardiac Changes: Shortened QT interval on ECG.

Differential Diagnosis and Patterns of Hyperparathyroidism

• Comparative Clinical and Laboratory Features:

Non-Parathyroid Causes of Hypercalcemia

• PTH-Dependent Etiologies:

  • Primary Hyperparathyroidism (adenoma/hyperplasia).

  • Tertiary Hyperparathyroidism.

  • Familial Hypocalciuric Hypercalcemia (FHH): Autosomal dominant inactivating mutation in the CaSR gene. Parathyroid cells perceive normal calcium as low, setting a higher threshold for PTH suppression. Features mild hypercalcemia, normal or slightly elevated PTH, and characteristically low 24-hour urinary calcium excretion.

• PTH-Independent Etiologies:

  1. Humoral Hypercalcemia of Malignancy (HHM):

  • Most common cause of hypercalcemia in hospitalized patients.

  • Malignant tumors (e.g., squamous cell carcinoma of lung, head, neck, esophagus, or renal cell carcinoma) secrete Parathyroid Hormone-Related Peptide (PTHrP).

  • PTHrP shares structural N-terminal homology with PTH and binds the PTH-1 receptor in bone and kidney, stimulating osteoclastic bone resorption and renal calcium reabsorption while inhibiting proximal phosphate reabsorption.

  • Biochemical Profile: Indistinguishable from primary hyperparathyroidism (Hypercalcemia + Hypophosphatemia), EXCEPT intact native PTH is suppressed ($< 0.5\,\text{pmol/L}$ or undetectable).

  1. Osteolytic Skeletal Metastases: Direct bone destruction by local tumor metastases (e.g., breast carcinoma, multiple myeloma) mediated by local cytokine release.

  2. Vitamin D Toxicity / Granulomatous Disease:

  • Caused by excessive exogenous intake or granulomatous disorders (sarcoidosis, tuberculosis, berylliosis) where activated macrophages express unregulated $1\alpha\text{-hydroxylase}$ activity.

  • Biochemical Profile: Elevated serum calcium AND elevated serum phosphate (calcitriol increases intestinal absorption of both ions), suppressed native PTH, and elevated calcitriol.

  1. Medications and Other Factors:

  • Thiazide diuretics (increased DCT calcium reabsorption).

  • Milk-Alkali Syndrome (excessive ingestion of calcium carbonate antacids).

  • Hyperthyroidism (increased bone turnover), prolonged immobilization.

Clinical Case Analysis: Vitamin D Intoxication

• Patient Presentation:

  • A 58-year-old male presents with 3 weeks of progressive fatigue, nausea, polyuria, abdominal pain, and mild confusion.

  • Medication History: High-dose Vitamin D drops (cholecalciferol $50{,}000\,\text{IU}$ daily) prescribed by a wellness clinic for 3 months, combined with over-the-counter calcium supplements ($1\,\text{g/day}$).

  • Physical exam reveals no nephrolithiasis or fractures.

• Laboratory Findings:

• Case Solutions and Physiological Explanations:

  • Q1. Diagnosis and Culprit:

  • Diagnosis: Exogenous Vitamin D Intoxication / Hypervitaminosis D.

  • Culprit: Excessive daily intake of cholecalciferol ($50{,}000\,\text{IU/day}$) combined with oral calcium supplementation.

  • Q2. Physiological Explanation of Abnormal Findings:

  • Elevated Calcitriol ($210\,\text{pmol/L}$): Massive substrate delivery ($50{,}000\,\text{IU/day}$ cholecalciferol) converted in the liver to calcidiol overwhelms regulatory control, driving excess synthesis of active calcitriol.

  • Elevated Serum Total Calcium ($3.45\,\text{mmol/L}$): High calcitriol hyper-stimulates intestinal enterocyte expression of TRPV6 and calbindin, maximizing transcellular absorption of dietary calcium. High calcitriol also increases renal tubular calcium reabsorption and mobilizes bone calcium.

  • Suppressed Intact PTH ($< 0.5\,\text{pmol/L}$): Severe hypercalcemia directly binds and activates parathyroid chief cell CaSR. High calcitriol directly represses PTH gene transcription, completely suppressing PTH synthesis.

  • Elevated 24-Hour Urine Calcium ($11\,\text{mmol/day}$): Severe hypercalcemia increases filtered glomerular calcium load beyond tubular reabsorptive capacity. Hypercalcemia activates renal CaSR in the TAL, suppressing NKCC2/ROMK and tight junction permeability, causing hypercalciuria.

  • Q3. Comparison of Phosphate Levels (Vitamin D Toxicity vs. Primary Hyperparathyroidism):

  • In Vitamin D Toxicity: Active calcitriol upregulates transporters for BOTH calcium AND phosphate in the gut and kidneys. Because PTH is suppressed, the phosphaturic effect of PTH is lost, producing Hyperphosphatemia ($1.9\,\text{mmol/L}$).

  • In Primary Hyperparathyroidism: Excess PTH directly inhibits proximal tubule sodium-phosphate cotransporters, producing marked phosphaturia that causes Hypophosphatemia.

  • Bonus Answer: Demonstrating an extremely elevated circulating $25\text{-(OH) Vitamin D}$ (Calcidiol) alongside elevated Calcitriol in the presence of suppressed PTH confirms that high precursor substrate concentration drives massive non-regulated hepatic 25-hydroxylation and extrarenal conversion.